Company news
Annji Pharmaceutical Co., Ltd. (TPEX:7754) news
Annji Pharmaceutical Co., Ltd. news releases on 6ix. Latest, Oct 5, 2026: AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal…
Press releases & updates
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
October 5, 2026
Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference
March 3, 2026
FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease
October 22, 2025
AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025
October 13, 2025